Developmental stage biopharmaceutical company Silo Pharma, Inc. (Nasdaq:SILO) announced on Monday positive results from a preclinical study on SPC-15.

This formulation targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), showing promise as a treatment for major depressive disorder (MDD) and other stress-related conditions.

Study findings suggest that combining SPC-15, a 5-HT4R agonist, with an NMDAR antagonist may provide enhanced efficacy for severe psychiatric disorders. In animal models, the dual-target approach yielded superior outcomes, reducing stress-related behaviours more effectively than either agent alone. The combination therapy may offer significant benefits for patients with treatment-resistant depression.

SPC-15 is designed as an intranasal medication and is being developed for conditions like PTSD and anxiety. Silo Pharma is conducting preclinical studies in partnership with Columbia University and holds an exclusive license to develop and commercialize SPC-15 globally. If successful, SPC-15 may qualify for the FDA's 505(b)(2) approval pathway.